08:00 , Nov 12, 2012 |  BC Week In Review  |  Clinical News

Augment Injectable Bone Graft regulatory update

BioMimetic disclosed in its 3Q12 earnings that it submitted a Device License Application (DLA) to Health Canada for Augment Injectable Bone Graft. In June, BioMimetic reported data from a Canadian pivotal trial to treat foot...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Clinical News

Augment Injectable Bone Graft: Pivotal trial data

A pivotal Canadian trial in 217 patients showed that Augment Injectable Bone Graft met the primary endpoint of non-inferiority to autograft in the proportion of patients who achieved >=50% osseous bone bridging as evaluated by...
07:00 , Mar 19, 2012 |  BC Week In Review  |  Clinical News

Augment Injectable Bone Graft: Phase III suspended enrollment

BioMimetic disclosed in its 4Q11 earnings that it voluntarily suspended screening and enrollment in a North American Phase III trial evaluating its Augment Injectable Bone Graft to focus on Augment Bone Graft. In January, the...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Clinical News

Augment Injectable Bone Graft: Phase III ongoing

In its 3Q11 earnings, BioMimetic said it proposed to expand enrollment to 300 patients in a North American Phase III trial evaluating its Augment Injectable Bone Graft to treat hindfoot fusions. The trial had been...
08:00 , Nov 3, 2008 |  BC Week In Review  |  Clinical News

Augment Injectable Bone Graft: Pilot trial data

In a pilot study in 21 evaluable patients with distal radial fractures, external fixation plus Augment Injectable Bone Graft (AIBG) resulted in earlier bone formation compared with patients who received external fixation only. Bone fill...
07:00 , Aug 18, 2008 |  BC Week In Review  |  Clinical News

Augment Injectable Bone Graft: Pilot trial data

Initial data from an open-label, Canadian pilot trial of Augment Injectable Bone Graft in 10 patients showed 100% clinical success based on measurements including ability to stand and walk without pain at 6-months post-surgery. The...
08:00 , Jan 29, 2007 |  BC Week In Review  |  Clinical News

GEM OS2: Pilot trial started

BMTI began a Swedish pilot trial in up to 20 patients. BioMimetic Therapeutics Inc. (BMTI), Franklin, Tenn.   Product: GEM OS2   Business: Musculoskeletal   Molecular target: Platelet derived growth factor (PDGF) receptor   Description:...
08:00 , Feb 13, 2006 |  BioCentury  |  Finance

Ebb & Flow

When OSI (OSIP) announced plans to buy Eyetech last year, angry shareholders took their pound of flesh by immediately driving the stock price down 22%. Their gripe was that they didn't think OSIP was buying...